Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/9/2018
SIETES contiene 92557 citas

 
 
 1 a 20 de 354 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, García-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018:26 de agosto. [Ref.ID 102827]
3. Cita con resumen
Anónimo. FDA approves appetite suppressant. DIA Daily 2016:2. [Ref.ID 100763]
4. Cita con resumen
Casassus B. Drug scandals in France: have the lessons been learnt?. Lancet 2016;388:550-2. [Ref.ID 100574]
5.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
6. Cita con resumen
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-34. [Ref.ID 100458]
7. Cita con resumen
Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, Timbo BB, Mozersky RP, Budnitz DS. Emergency department visits for adverse events related to dietary supplements. N Engl J Med 2015;373:1531-40. [Ref.ID 99589]
8. Cita con resumen
Montastruc F. Psichopharmacologie des révolutions?. Bulletin d'Information de Pharmacologie 2015;22:37. [Ref.ID 99555]
9. Cita con resumen
Anónimo. Dangers de l'anorexigène Mysimba: mobilisation citoyenne bienvenue. Prescrire 2015;35:305. [Ref.ID 99129]
10. Cita con resumen
Cunill R, Castells X. Trastorno por déficit de atención con hiperactividad. Med Clin (Barc) 2015;144:370-5. [Ref.ID 98996]
11. Cita con resumen
Anónimo. Lisdexamfetamine /Vyvanse) for binge eating disorder. Med Lett Drugs Ther 2015;57:42. [Ref.ID 98884]
12. Cita con resumen
Anónimo. FDA approves weight-management drug Saxenda. FDA U.S. Food and Drug Administration 2014:23 de diciembre. [Ref.ID 98393]
13.
Rueda-Clausen CF, Padwal RS. Pharmacotherapy for weight loss. BMJ 2014;348:g3526. [Ref.ID 98045]
14. Cita con resumen
Woloshin S, Schwartz LM. The new weight-loss drugs, Lorcaserin and Phentermine-topiramate. Slim pickings?. JAMA Intern Med 2014;174:615-9. [Ref.ID 97426]
15. Cita con resumen
Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626. [Ref.ID 97343]
16. Cita con resumen
Anónimo. lorcasérine (Belviq). Obésité: prise de risque inacceptable. Prescrire 2014;34:99. [Ref.ID 97125]
17. Cita con resumen
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86. [Ref.ID 97034]
18. Cita con resumen
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2013;311:74-86. [Ref.ID 96313]
19.
Astrup A, Madsbad S, Breum L, Jensen TJ. Under-reporting of adverse effects of tesofensine. Lancet 2013;382:127. [Ref.ID 95827]
20. Cita con resumen
Mullard A. Mediator scandal engulfs French compensation body. Lancet 2013;381:1803. [Ref.ID 95500]
Seleccionar todas
 
 1 a 20 de 354 siguiente >>